Skip to content
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Menu
Search
Toggle Menu
Change Country
Our Stories
Latest News
Innovation
Caring & Giving
Personal Stories
Health & Wellness
Our Heritage
Our Company
Our COVID-19 Efforts
The Road to a Vaccine
About J&J
Our Credo
Our Leadership Team
Diversity, Equity & Inclusion
Veterans, Military & Military Families
Innovation at J&J
J&J Health and Wellness Solutions
ESG Policies & Positions
Code of Business Conduct
Corporate Reports
Products
Consumer Health Products
Medical Devices
Pharmaceutical Products
Procurement
Value Pillars
Supplier Diversity
Supplier Standards
Careers
What We Do
How We Hire
Job Spotlight
Employee Benefits
Students
Innovation
Career Stories
Media Center
Investors
2021 Annual Shareholders Meeting
Corporate Governance
Quarterly Results
SEC Filings
News Releases
Pharmaceutical Pipeline
2020 Janssen Transparency Report
2019 Health for Humanity Report
ESG Resources
Stock Information
Webcasts & Presentations
Investor Fact Sheet
Our Societal Impact
Global Community Impact
Global Public Health
Global Environmental Health
Sustainability Reporting
Follow Us
Facebook
facebook
Instagram
instagram
LinkedIn
linkedin
Twitter
twitter
YouTube
youtube
Close Countries Menu
Explore more Johnson & Johnson sites:
Australia
alt
Argentina
alt
Brazil
alt
Canada
alt
Chile
alt
China
alt
Colombia
alt
Costa Rica
alt
Czech Republic
Ecuador
alt
Germany
alt
India
alt
Japan
alt
Mexico
alt
New Zealand / Pacific
alt
Paraguay
alt
Peru
alt
Philippines
alt
Russia
alt
Switzerland
alt
German
English
French
United States
alt
Uruguay
alt
Venezuela
alt
Close Search Menu
Search input
Johnson & Johnson COVID-19 Vaccine Roll-out to Resume in Europe Following EMA Review
Learn More
Share
Investor Information
Johnson & Johnson First Quarter 2021 Earnings Call and Webcast
Johnson & Johnson First Quarter 2021 Earnings Call and Webcast
Learn More
2021 Annual Meeting of Shareholders
Johnson & Johnson to Participate in the BofA Securities Virtual 2021 Healthcare Conference
Register for Webcast: Raymond James 42
nd
Annual Institutional Investors Conference
NYSE: JNJ
$166.48
$3.79 (
2.330
%)
Day High
$167.79
Day Low
$161.00
Volume
14,050,660
Last Updated:
4/20/2021 04.10 PM
Our Company
Save the Date: 2021 Business Review
Our business review focused on the
Pharmaceuticals Sector
will be held on
November 18, 2021
. Please save the date, and check back here for more details to follow.
Latest News Releases
Our Company
March 29, 2021
Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company’s COVID-19 Vaccine Candidate
Innovation
March 26, 2021
Janssen Receives Positive CHMP Opinion for PONVORY™ (ponesimod) for the Treatment of Adults With Relapsing Forms of Multiple Sclerosis With Active Disease Defined by Clinical or Imaging Features
Innovation
March 19, 2021
Janssen Announces U.S. FDA Approval of PONVORY™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio
®
(teriflunomide) in Reducing Annual Relapses and Brain Lesions
See All News Releases
Webcast: 2020 Medical Devices Update
Webcast: 2020 Medical Devices Update
ON NOW
Webcast: 2020 Medical Devices Update
2019 Health for Humanity Report
2019 Health for Humanity Report
ON NOW
2019 Health for Humanity Report
2020 Janssen U.S. Transparency Report
2020 Janssen U.S. Transparency Report
ON NOW
2020 Janssen U.S. Transparency Report
2020 Annual Report
2020 Annual Report
ON NOW
alt
2020 Annual Report
Investor Relations
Corporate Governance
Corporate Governance
ON NOW
alt
Corporate Governance
SEC Filings
SEC Filings
ON NOW
SEC Filings
Pharmaceutical Pipeline
Pharmaceutical Pipeline
ON NOW
Pharmaceutical Pipeline
Stock Information
Stock Information
ON NOW
Stock Information
Webcasts & Presentations
Webcasts & Presentations
ON NOW
Webcasts & Presentations
Investor Fact Sheet
Investor Fact Sheet
ON NOW
Investor Fact Sheet
Quarterly Results
See the latest quarterly sales and earnings from Johnson & Johnson, as well as historical results covering the past ten years.
Learn More
Shareholder Tools
Email Alerts Subscription
RSS News Feeds
Investor FAQs
Answers to common questions regarding purchasing and owning Johnson & Johnson stock.
Learn More
ESG Resources
Effective management of ESG matters is a business imperative.
Learn More
Contact Investor Relations
Questions? Please contact Investor Relations:
1-800-950-5089
Learn more about our Guidelines for Communication with the Investment Community (Reg FD)
This site uses cookies as described in our
Cookie Policy
Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Accept